Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Letter to the Editors-in-Chief

Rotational thromboelastometry to assess hypercoagulability in COVID-19 patients

Coronavirus disease 2019 (COVID-19) has spread rapidly around the world, affecting more than 23 million people so far [1]. Besides typical respiratory symptoms, COVID-19 is associated with coagulation abnormalities leading to thromboembolic complications [2]. In COVID-19 patients admitted to the Intensive Care Unit (ICU), the incidence of thromboembolic complications is approximately 31–49% [3,4].

Monitoring of standard coagulation variables in COVID-19 is recommended due to the associated coagulopathy. However, conventional coagulation tests reflect limited parts of the coagulation cascade. Currently, no test reliably identifies which COVID-19 patients are at the highest risk of developing thromboembolic complications.

Rotational thromboelastometry (ROTEM®) is a point-of-care device that evaluates viscoelastic changes during coagulation and enables identification of hypercoagulability [5]. Hence, ROTEM® profiles may be useful to identify COVID-19 patients at risk of developing thrombosis.

In this single-center retrospective observational study, we aimed to evaluate ROTEM® profiles of COVID-19 patients admitted to the ICU and to compare the ROTEM® profiles of COVID-19 patients with and without thromboembolic complications.

Patients diagnosed with COVID-19 admitted to the ICU in April 2020 were enrolled. COVID-19 was diagnosed according to World Health Organization (WHO) definition and was confirmed by RNA detection of the SARS-CoV-2 using the polymerase chain reaction (PCR)-based technique. Patients received thromboprophylaxis with low molecular weight heparin (LMWH) according to local protocol (at time of study, nadroparin 2850E od). Patient characteristics, clinical data, and outcomes were collected. Coagulation variables were collected as part of standard clinical care, including prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen, and platelet count.

Blood samples were collected and ROTEM® was carried out using a coagulation analyzer (ROTEM® Sigma; Werfen, The Netherlands). Three and a half milliliters of citrated blood was collected for each COVID-19 patient and processed within 6 h.

Coagulation patterns were analyzed using extrinsic and intrinsic activators (EXTEM and INTEM). The influence of fibrinogen on clot firmness was analyzed using the platelet inactivating FIBTEM test. All samples were run for at least 30 min. The following variables were recorded and analyzed: clotting time (CT), clotting formation time (CFT), clot firmness’ amplitude after 5 min (AS) and after 10 min (A10), and maximum clot firmness (MCF). Hypercoagulability was defined as a reduction in CFT and an increase in MCF compared to reference values from healthy patients [3]. All normal values are displayed in the tables.

Patients who were clinically suspected of having a thromboembolic complication, underwent additional imaging during ICU admission. A thromboembolic complication was defined as a pulmonary embolism (PE) or deep venous thrombosis (DVT; either catheter-related or not).

Our results show changes in ROTEM® variables supporting the presence of a hypercoagulable state in COVID-19 patients. ROTEM® profiles of COVID-19 patients showed a decreased CFT and increased MCF. The increased CT in EXTEM corresponds with prolonged PT and APTT in the conventional coagulation test. Standard coagulation variables showed higher fibrinogen levels in COVID-19 patients compared to normal, consistent with findings in other studies [2]. The influence of fibrinogen on clot firmness was confirmed by the high MCF in FIBTEM.

Visco-elastic coagulation testing, such as ROTEM®, is gaining importance as a bedside diagnostic test for the early identification of coagulopathy in COVID-19 patients and for monitoring the response to treatment. Further studies are needed to validate the clinical utility of ROTEM® in a larger cohort of COVID-19 patients.
The development of thromboembolic complications in COVID-19 patients might be explained by inflammatory changes and coagulation abnormalities. However, specific ICU factors such as immobilization, sedation, fluid restriction, use of vasopressors, central venous catheters, and vascular damage can also increase the risk of thrombosis. The risk on thromboembolic complications should be considered in light of these confounders.

Hypercoagulability might be associated with other clinical characteristics besides COVID-19. An increased MCF with ROTEM® analysis was also found in patients with severe sepsis and shock [5]. A larger MCF in EXTEM and INTEM can also be found in obese patients. Central obesity was found to be a predictor of a hypercoagulable state evaluated by ROTEM® analysis [10].

There were several limitations. First, the sample size of this observational study was rather small, increasing the vulnerability to confounding factors. Second, screening for thromboembolic complications was not standardized, and imaging was based on clinical suspicion. Therefore, only a minority of the patients underwent a CT-scan. Last, ROTEM® analysis was not performed on a pre-specified day after ICU admission. However, hypercoagulability in COVID-patients seems to persist over time [9].

In this study, ROTEM® analysis confirmed the hypercoagulable state of COVID-19 patients admitted to the ICU. However, our study does not support the use of ROTEM® in identifying COVID-19 patients at risk for developing thromboembolic complications. Further study into the hypercoagulability in COVID-19 patients admitted to the ICU is needed to confirm our findings and to define the clinical value in subgroup of patients. Also, future studies may investigate the effectiveness of ROTEM®-guided, individualized anticoagulation dosing in COVID-19 patients admitted to the ICU.

### Table 1
Baseline characteristics of COVID-19 patients (n = 47).

| Characteristic                  | Value (range) |
|--------------------------------|---------------|
| Age, years - median, IQR       | 63 (29-79)    |
| Sex - n (%)                    |               |
| Male                           | 38 (81)       |
| Female                         | 11 (19)       |
| BMI, kg/m² - median, IQR       | 28.8 (24.4-48.4) |
| Mechanically ventilated - n (%)| 47 (100)      |
| APACHE IV score - median, IQR  | 63 (15-108)   |
| SAPS II score - median, IQR    | 42 (17-70)    |
| CCI score - median, IQR        | 3.6 (0-12)    |
| Length of ICU admission at the time of the study, days - median, IQR | 8 (1-25) |
| Total length of ICU stay, days - median, IQR | 18 (7-47)   |
| Anticoagulant - n (%)          |               |
| Prophylactic LMWH              | 41 (87%)      |
| Therapeutic LMWH               | 2 (4%)        |
| Unfractionated heparin         | 4 (9%)        |
| CT - n (%)                     |               |
| No CT                          | 17 (36%)      |
| 30 (64%)                       |
| Thromboembolic complication - n (%) | 10 (21%)  |
| No thromboembolic complication | 37 (79%)      |
| ICU outcome - n (%)            |               |
| Alive to ward and home         | 40 (85%)      |
| Death                          | 7 (15%)       |

### Abbreviations: BMI = Body Mass Index; APACHE IV = Acute Physiology And Chronic Health Evaluation; SAPS = Simplified Acute Physiology Score; CCI = Charlson Comorbidity Index; LMWH = low molecular weight heparin; ICU = Intensive Care Unit; CT = Computed Tomography.

popularity because of its ability to offer a rapid and detailed evaluation of the clotting process. Although mainly used in low blood loss, ROTEM is also used to detect thrombosis [5]. ROTEM also manages to measure hypercoagulability, where it is not detected by conventional coagulation tests.

Severe hypercoagulability in COVID-19 patients has recently been demonstrated in other visco-elastic hemostatic assays, such as the Quantra and TEG [6,7]. The results of our study are consistent with the findings of two other studies on ROTEM® profiles showing a decreased CFT and higher MCF [8,9]. Only one study on visco-elastic coagulation testing in COVID-19 patients reported the incidence of thromboembolic complications in their study cohort [9].

Contrary to expectations, clot firmness was lower and CFT longer in patients with thromboembolic complications. The finding of more thromboembolic complications in patients with normal ROTEM® tracing might be explained by coincidence. Also, heparin could have an effect on ROTEM® outcomes and all patients had prophylactic anticoagulation at the time of ROTEM® measurements. More studies are required to study the ROTEM® profiles of COVID-19 patients with thromboembolic complications.

### Table 2
ROTEM® variables and conventional coagulation variables in COVID-19 patients with and without thromboembolic complications.

| ROTEM® parameter | Normal range (SD) | All COVID-19 patients (n = 47), mean (SD) | Thromboembolic complications (n = 10), mean (SD) | No thromboembolic complications (n = 37), mean (SD) | P-value |
|------------------|-------------------|------------------------------------------|-----------------------------------------------|------------------------------------------------|--------|
| EXTEM CT, s      | 53-83 (20.6)      | 54.1 (8.4) (SD)                         | 58.5 (7.8)                                  | 68.0 (7.2)                                   | 64.3 (5.4) | 0.01 |
| EXTEM A5, mm     | 32-52 (6.4)       | 45.3 (10.0)                              | 53.3 (15.9)                                 | 72.4 (4.4)                                   | 72.9 (3.3) | 0.02 |
| EXTEM A10, mm    | 43-63 (5.3)       | 71.5 (5.3)                               | 70.5 (6.1)                                  | 73.5 (4.5)                                   | 77.9 (3.3) | 0.05 |
| EXTEM MCF, mm    | 55-72 (4.1)       | 77.3 (4.1)                               | 75.0 (5.9)                                  | 77.9 (3.3)                                   | 77.9 (3.3) | 0.001 |
| INTEM CT, s      | 168-212 (25.0)    | 177.6 (25.0)                             | 184.5 (18.5)                                | 175.7 (26.3)                                 | 175.7 (26.3) | 0.30 |
| INTEM A5, mm     | 32-52 (7.4)       | 45.6 (12.6)                              | 53.3 (15.9)                                 | 43.5 (11.2)                                  | 43.5 (11.2) | 0.03 |
| INTEM A10, mm    | 43-62 (6.4)       | 65.3 (6.4)                               | 61.6 (7.5)                                  | 66.2 (5.8)                                   | 66.2 (5.8) | 0.04 |
| INTEM MCF, mm    | 51-69 (5.0)       | 72.9 (5.0)                               | 70.5 (6.1)                                  | 73.5 (4.5)                                   | 73.5 (4.5) | 0.09 |
| FIBTEM MCF, mm   | 6-21 (6.4)        | 32.9 (6.4)                               | 31.1 (8.3)                                  | 33.3 (5.8)                                   | 33.3 (5.8) | 0.33 |

| Conventional coagulation variables | Value (range) |
|------------------------------------|---------------|
| Platelet count, 10³/L              | 150-400       |
| PT, s                              | 10.2-13.3     |
| APTT, s                            | 25-36         |
| Fibrinogen, g/L                    | 2-3.9         |

| Platelet count, 10³/L              | 404 (154)     |
| PT, s                              | 15.3 (2.0)    |
| APTT, s                            | 34.7 (8.7)    |
| Fibrinogen, g/L                    | 7.2 (1.6)     |

| Platelet count, 10³/L              | 350 (208)     |
| PT, s                              | 14.9 (2.1)    |
| APTT, s                            | 32.6 (3.4)    |
| Fibrinogen, g/L                    | 7.1 (1.9)     |

Abbreviations: ROTEM® = rotational thromboelastometry; INTEM = intrinsic rotational thromboelastometry; EXTEM = extrinsic rotational thromboelastometry; FIBTEM = fibrinogen rotational thromboelastometry; CT = clotting time; CFT = clot formation time; A5 = amplitude after 5 min; A10 = amplitude after 10 min; MCF = maximum clot firmness; PT = prothrombin time; APTT = activated partial thromboplastin time.

380
Declaration of competing interest

The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of the article.

Outside the submitted work, Thomas Scheeren received research grants and honoraria from Edwards Lifesciences (Irvine, CA, USA) and Masimo Inc. (Irvine, CA, USA) for consulting and lecturing and from Pulson Medical Systems SE (Feldkirchen, Germany) for lecturing. TWLS is chair of the Cardiovascular Dynamics section of the European Society of Intensive Care Medicine (ESICM). Not related to the submitted work, Karina Meijer received research grants from Pfizer, and research grants from Bayer and Sanquin and for lecturing, and from Boehringer Ingelheim, BMS and Aspen for lecturing, and from Uniqure for consulting.

References

[1] World Health Organization, Coronavirus Disease (COVID-19) Weekly Epidemiological Update 23 August 2020, World Health Organization, Geneva, Switzerland, 2020 Available at https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports, Accessed date: 26 August 2020.

[2] C. Lodigiani, G. Iapichino, L. Carenzo, et al., Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy, Thromb. Res. 191 (2020) 9–14, https://doi.org/10.1016/j.thromres.2020.04.024.

[3] J. Helms, C. Tacquard, F. Severac, et al., High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study, Intensive Care Med. 46 (2020) 1089–1098, https://doi.org/10.1007/s00134-020-06063-x.

[4] F.A. Klok, M.J.H.A. Kruip, N.J.M. van der Meer, et al., Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis, Thromb. Res. 191 (2020) 148–150, https://doi.org/10.1016/j.thromres.2020.04.041.

[5] O.M. Akay, The double hazard of bleeding and thrombosis in hemostasis from a clinical point of view: a global assessment by rotational thromboelastometry (ROTEM), Clin. Appl. Thromb. Hemost. 24 (2018) 850–858, https://doi.org/10.1177/1076029618772336.

[6] M. Ranucci, A. Ballotta, U. Di Dedda, et al., The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome, J. Thromb. Haemost. (2020), https://doi.org/10.1111/jth.14854 Apr 17.

[7] M. Panigada, N. Botinot, P. Tagliabue, et al., Hypercoagulability of COVID-19 patients in intensive care unit. A report of thromboelastograph findings and other parameters of hemostasis, J. Thromb. Haemost. (2020), https://doi.org/10.1111/jth.14850 Apr 17.

[8] L. Spiezia, A. Boscolo, F. Poletto, L. Cerruti, I. Tiberio, E. Campello, P. Navalesi, P. Simioni, COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure, Thromb. Haemost. 120 (2020) 998–1000, https://doi.org/10.1055/s-0040-1710018.

[9] V. Pavoni, L. Gianesello, M. Pazzi, et al., Evaluation of coagulation function by rotation thromboelastometry in critically ill patients with severe COVID-19 pneumonia, J. Thromb. Thrombolysis 11 (2020) 1–6, https://doi.org/10.1007/s11239-020-02130-7.

[10] E. Campello, L. Spiezia, E. Zabeo, et al., Hypercoagulability detected by whole blood thromboelastometry (ROTEM®) and impedance Aggregometry (MULTIPLATE®) in obese patients, Thromb. Res. 135 (2015) 546–553, https://doi.org/10.1016/j.thromres.2015.01.003.

Nadine van Veenendaal*a,c, Thomas W.L. Scheeren*b,c, Karina Meijerc, Peter H.J. van der Voorta

a Department of Critical Care, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, the Netherlands

b Department of Anesthesiology, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, the Netherlands

c Department of Hematology, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, the Netherlands

E-mail addresses: n.van.veenendaal@umcg.nl (N. van Veenendaal), t.w.l.scheeren@umcg.nl (T.W.L. Scheeren), k.meijer@umcg.nl (K. Meijer), p.h.j.van.der.voort@umcg.nl (P.H.J. van der Voort).

* Corresponding author at: Department of Critical Care, University Medical Centre Groningen, P.O. Box 30.001, 9700 RB Groningen, the Netherlands.